



MINUTES

Utah Department of Health
Drug Utilization Review Board

Thursday, September 8th, 2016
7:15 a.m. to 8:30 a.m.
Cannon Health Building
Room 125

Board Members Present

Jennifer Brinton, M.D., Board Chair
Neal Catalano, Pharm D.
Steve Lore, M.D.
Holly Gurgle, Pharm D.
Katherine Smith, Pharm D.
Aesha Drozdowski, Pharm D.

Keith Tolman, M.D.
Susan Siegfried, M.D.
Michael Symond, M.D.
Kumar Shah, M.Sc., P.Eng.
Ben Berrett, Pharm D.

Board Members Excused: N/A

Dept. of Health/Div. of Health Care Financing Staff Present:

Chad Hope, Pharm D
Robyn Seely, Pharm D.
Alyssa Pitts, R.N.
Megan Schlappi, C.Ph.T.

Heather Santacruz, R.N.
Merelynn Berrett, R.N
Bryan Larson, Pharm.D.

Other Individuals Present:

Joanita Lake, UofU*
Kelly Ponce, AstraZeneca
Lori Blackner, Pfizer
Cody Ball, Select Health
Laura Britton, Healthy U

Rupa Shah, Purdue Pharma
Alan Bailey, Pfizer
Blake Burton, UofU*
Tim Grange, M.D.

*UofU = University of Utah

Meeting conducted by: Jennifer Brinton, M.D.

1. **Welcome & Housekeeping:** Jennifer Brinton opened the meeting and reminded everyone to sign the rosters.
 - a. Robyn Seely introduced Dr. Aesha Drozdowski as a new Pharmacist on the board.
 - b. Robyn Seely explained the purpose of the proposed DUR Board By-Laws. Keith Tolman expressed his concern with Section 7-Removal. Keith Tolman made a motion to remove the words "but is not limited to"... And to add the words "in consultation with the board" in section 7. Section 7 would now read...

“Any member of the DUR Board may be removed by the Director for good cause. Good cause shall include the following:

- A. Nonattendance
 - a. Three consecutive absences from scheduled meetings shall constitute a resignation.
 - b. Four absences from six consecutive scheduled meetings shall constitute a resignations.
 - B. Wrongdoing or misconduct while in membership, in consultation with the board.”
- c. Kumar Shah seconded. 10 board members approved. Katherine Smith abstained. Motion carries. Mike Symond made a motion to accept the proposed by-laws (with the previous motion included). Kumar Shah seconded. All in favor.
2. **Review and Approval of August Minutes:** Kumar Shah made a motion to approve the minutes from the August meeting. Mike Symond seconded. 9 board members approved. Keith Tolman and Aesha Drozdowski abstained. Motion carried.
 3. **Pharmacy and Therapeutics (P&T) Committee update:** Bryan Larson, P&T Manager, updated the board on the P&T Committee. The P&T Committee met last month to discuss “Other Antidepressants/Serotonergic Agents”. The Committee made a motion to include at least one formulation of atomoxetine, lithium and bupropion as preferred on the PDL. The Committee also made a motion that there be at least three preferred agents on the PDL from the antidepressant miscellaneous class (that class being: bupropion, trazadone, mirtazapine, nefazodone, vilazodone and vortioxetine).
 4. **9 Month Review:** N/A
 5. **Reconsideration of Prior Authorization Criteria:** The Board reviewed outdated clinical PA criteria. They motioned to remove the clinical prior authorization criteria for the following: Dipeptidyl Peptidase IV (DPP-4) Inhibitors, Glucagon-Like-Peptide-1 (GLP-1) Receptor Agonists, Sodium-Glucose Co-transporter 2 (SGLT-2) Inhibitors, Thiazolidinediones (TZDs). Mike Symond made a motion to remove the Prior Authorization criteria on these medications. Keith Tolman seconded. 10 board members approved. Neal Catalano abstained. Motion carried.
 6. **Long Acting Opiates:** Joanita Lake from the University of Utah Drug Regimen Review Center presented drug information including disease symptoms, studies, side effects, indications and other information about the products. Data was also presented about the utilization of the drugs in the Utah Medicaid population.
 7. **Public Comments:**
 - a. Rupa Shah, Pharm.D. Purdue- Yielded her time.
 - b. Lori Blackner, Pharm.D. Pfizer- Lori Blackner discussed the product Hysingla ER and the benefits of abuse deterring medications.
 - c. Tim Grange, MD, Spine, Orthopedic & Pain Center- Tim Grange discussed his work at his practice dealing with pain and addiction. He expressed concern with the PDL and the drugs that are preferred vs. non-preferred.

8. Board Discussion:

- a. Chad Hope reminded everyone about the difference between the DUR board and the P&T Committee. He explained that Preferred Drug List (PDL) questions should not be addressed, as the PDL is not something that the DUR board discusses.
- b. Joanita Lake explained to the board that the report that was put together by the University of Utah Drug Regimen Review Center only discussed opioid agonists, not partial opioid agonists or mixed agonist/antagonist agents, so products like Suboxone are not under discussion.
- c. Steve Lore expressed concerns with the proposed quantity limits, specifically for MS Contin and methadone. He explained that many patients need to work up to certain doses, and limiting these drugs to twice daily dosing does not allow for that. He agreed with Dr. Tim Grange that by putting limits on certain medications, there can be unintended consequences that can actually push physicians to prescribe higher doses than needed.
- d. Keith Tolman suggested that the board try to focus more on duration of therapy, indications and risk factors, instead of focusing on quantity limits. He also suggested closing the meeting and reconvening next month.
- e. Steve Lore made a motion to increase the quantity limits on MS Contin 30mg and 60mg, plus methadone 5mg and 10mg to allow for TID (three times daily) dosing. No second. Motion fails.
- f. Due to time restraints, Keith Tolman made a motion to finish the discussion and look specifically at indications at the next DUR board meeting. Mike Symond seconded. All in favor.

9. Public Meeting Adjourned

10. Next meeting is scheduled for October 13th, 2016.

Audio recordings of DUR meetings are available online at:

[https://medicaid.utah.gov/pharmacy/drug-utilization-review-board?p=DUR Board Audio Recordings/](https://medicaid.utah.gov/pharmacy/drug-utilization-review-board?p=DUR%20Board%20Audio%20Recordings/)